Maxcyte (MXCT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$31.1M

Revenue (quarter)

$7.3M

Revenue growth (year over year)

−14.53%

Gross profit (trailing twelve months)

$24.6M

Gross margin

79.23%

Net income (trailing twelve months)

−$35.6M

Net income (quarter)

−$8.9M

Net income growth (year over year)

+28.19%

Net margin

−114.77%

Return on equity

−20.39%

EPS (trailing twelve months)

−$0.34

Book value per share

$1.50

P/E (trailing twelve months)

—

Price to book

0.81

Debt to assets

14.04%

Payout ratio

—

Dividend yield

—

Company profile

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

• Is Maxcyte (MXCT) profitable?

  No. Maxcyte reported a net loss of $35.6M over the trailing twelve months.

• How much revenue does Maxcyte (MXCT) make?

  Maxcyte generated $31.1M in revenue over the trailing twelve months, down 14.53% year over year.

• How do I buy stock in Maxcyte (MXCT)?

  MXCT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.